Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (1) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.
Type:
Application
Filed:
August 3, 2017
Publication date:
January 25, 2018
Applicant:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
José Miguel VELA HERNANDEZ, Daniel ZAMANILLO-CASTANEDO
Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to 1,9-diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
Type:
Application
Filed:
November 20, 2015
Publication date:
December 14, 2017
Applicant:
Laboratorios del Dr. Esteve, S.A.
Inventors:
Marina VIRGILI-BERNADO, Carlos ALEGRET-MOLINA, Carmen ALMANSA-ROSALES
Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
Type:
Application
Filed:
June 2, 2015
Publication date:
November 2, 2017
Applicant:
Laboratorios del Dr. Esteve, S.A.
Inventors:
Marina VIRGILI-BERNADO, Monica ALONSO-XALMA, Carlos ALEGRET-MOLINA, Carmen ALMANSA-ROSALES, Monica GARCIA LOPEZ
Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
Type:
Application
Filed:
July 2, 2015
Publication date:
November 2, 2017
Applicant:
Laboratorios del Dr. Esteve, S.A.
Inventors:
Félix CUEVAS-CORDOBÉS, Miguel Angel PERICÁS-BRONDO
Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms.
Type:
Grant
Filed:
May 18, 2012
Date of Patent:
October 17, 2017
Assignee:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
Jose Miguel Vela Hernandez, Maria Isabel Martin Fontelles
Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.
Type:
Grant
Filed:
August 2, 2011
Date of Patent:
October 17, 2017
Assignee:
Laboratorios Del Dr. Esteve, S.A.
Inventors:
José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
Type:
Grant
Filed:
December 17, 2012
Date of Patent:
October 17, 2017
Assignees:
LABORATORIOS DEL DR. ESTEVE, S.A., FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA—CAIXA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.
Type:
Grant
Filed:
February 4, 2011
Date of Patent:
September 12, 2017
Assignee:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
José Miguel Vela Hernández, Daniel Zamanillo-Castanedo
Abstract: The invention relates to a method and a diagnostic kit for monitoring HIV specific T cell responses and identifying subjects capable of controlling HIV progression or preventing HIV infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a large set of effector functions. The method is also suitable to detect T cell responses of any desirable cytokine or combination of cytokines to any pathogen.
Type:
Grant
Filed:
March 22, 2013
Date of Patent:
July 18, 2017
Assignees:
LABORATORIOS DEL DR. ESTEVE S.A., FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA—CAIXA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIOS AVANÇATS
Inventors:
Marta Ruiz Riol, Christian Brander, Javier Ibarrondo
Abstract: The present invention relates to new fused imidazolyl derivatives having a high affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
June 13, 2017
Assignee:
LABORATORIOS DEL DR. ESTEVE S.A.
Inventors:
José-Luis Díaz-Fernández, Carmen Almansa-Rosales, Piotr Nieczypor
Abstract: The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.
Type:
Application
Filed:
January 10, 2017
Publication date:
April 27, 2017
Applicant:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
José Manuel Baeyens-Cabrera, Helmut H. Buschmann, José-Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo, Francisco Rafael Nieto-López
Abstract: The present invention relates to new 1,2,3-triazole-amine derivatives, having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments for the treatment of sigma receptor related diseases and disorders.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
April 4, 2017
Assignee:
LABORATORIOS DEL DR. ESTEVE S.A.
Inventors:
Antoni Torrens-Jover, Ute Christmann, Josè-Luis Diaz-Fernández, Carmen Almansa-Rosales
Abstract: The invention relates to a method for rapid immunogen selection (RIS) based on the binding a library of recombinant viruses containing randomized HIV gp120 variants of a surface polypeptide displayed to said neutralizing antibodies. The invention relates as well to the use of the HIV gp120 immunogens isolated according to the RIS method of the invention in medicine for the treatment of diseases caused by a virus and in diagnosis for the identification of neutralizing antibodies in a patient.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
March 28, 2017
Assignees:
LABORATORIOS DEL DR. ESTEVE, S.A., FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA
Inventors:
María Eloísa Yuste Herranz, Víctor Sánchez Merino, Carolina Ferreira
Abstract: Pyrazolo[3,4-d]pyrimidine compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as a process for preparing these compounds, compositions comprising them and their use as medicaments.
Type:
Grant
Filed:
July 13, 2012
Date of Patent:
February 14, 2017
Assignee:
LABORATORIOS DEL DR. ESTEVE S.A.
Inventors:
Maria Rosa Cuberes-Altisent, Jordi Corbera-Arjona, Jose Luis Diaz-Fernandez, Carmen Almansa-Rosales
Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Type:
Application
Filed:
August 9, 2016
Publication date:
February 2, 2017
Applicant:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
Carlos Ramon PLATA SALAMAN, Nicolas TESSON
Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Type:
Application
Filed:
July 12, 2016
Publication date:
January 5, 2017
Applicant:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
Carlos Ramon PLATA SALAMAN, Nicolas TESSON
Abstract: The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.
Type:
Grant
Filed:
September 14, 2012
Date of Patent:
December 13, 2016
Assignee:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
Antoni Torrens Jover, Ramon Mercè Vidal, Francesc Xavier Caldentey Frontera, Antonio David Rodríguez Garrido, Elena Carceller González, Jordi Salas Solana
Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
Type:
Grant
Filed:
April 21, 2014
Date of Patent:
December 6, 2016
Assignee:
LABORATORIOS DEL DR. ESTEVE S.A.
Inventors:
José-Luís Díaz-Fernández, Carmen Almansa-Rosales, Félix Cuevas-Cordobés
Abstract: The present invention relates to new indene derivatives of formula (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
Type:
Grant
Filed:
July 3, 2013
Date of Patent:
November 15, 2016
Assignee:
LABORATORIOS DEL DR. ESTEVE S.A.
Inventors:
Maria de las Ermitas Alcalde-Pais, Carmen Almansa-Rosales, José´Luis Diaz Fernández, María de les Neus Mesquida-Estevez, Laura Paloma-Romeu
Abstract: The invention refers to compounds of general formula (I) wherein the variables take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in pain therapy.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
October 11, 2016
Assignee:
LABORATORIOS DEL DR. ESTEVE S.A.
Inventors:
Antoni Torrens-Jover, Rosa Ortuño-Mingarro, Àlex Pericas-Cano, Èric Ferrer-Mallofrè